clinical hematology
Contributions
Type: Publication Only
Background
Myelodysplastic syndromes (MDS) are a disorder of hematopoietic stem cell that affects essentially old population.
Aims
In this study we aim to show characteristics of management of MDS in our department and give a small example about Moroccan way to treat them with a few resources.
Methods
This is a retrospective study including all patients managed in our training for MDS since 2006 to February 2015.
Results
A total of 78 patients were included. The median age was 65.94 years; the rate of men was more likely higher than women with a sex ratio [M/F] of 1.7. At diagnosis, the international prognosis scoring system (IPSS) was calculated for only 85, 89 % (67 patients), 41.79% (28 patients) had low risque, 35.82%(24 patients) had intermediate 1 IPSS,14.92% (10 patients) intermediate 2,just five patients had a high risque with range of 7%.Reviesed IPSS(R-IPSS) was also calculated for only 61 patients (78%),9.8% had a very low R-IPSS,44.26% had low risque,29.5 % had intermediate risque,10 patients had high ( 9%) and very high (6,55%) risque. Concerning management, we decided to wait and see for 41% of patients, 34.6% needed best supportive care, Erythropoietin was prescribed for 28% of our patients, 21.7% received Azacithidine, three of our patients had Hydroxyurea,one of them had Thalidomide, and only two of them have been selected to have an allo stem cell l transplantation . Overall Follow up is about 42 months. The overall survival rate was 77, 78% at 2 years, and 44, 44% at 5 years.
Summary
Despite our few resources our results are the same of most publications concerning survivals in MDS.
Keyword(s): MDS, Patient, Treatment
Session topic: Publication Only
Type: Publication Only
Background
Myelodysplastic syndromes (MDS) are a disorder of hematopoietic stem cell that affects essentially old population.
Aims
In this study we aim to show characteristics of management of MDS in our department and give a small example about Moroccan way to treat them with a few resources.
Methods
This is a retrospective study including all patients managed in our training for MDS since 2006 to February 2015.
Results
A total of 78 patients were included. The median age was 65.94 years; the rate of men was more likely higher than women with a sex ratio [M/F] of 1.7. At diagnosis, the international prognosis scoring system (IPSS) was calculated for only 85, 89 % (67 patients), 41.79% (28 patients) had low risque, 35.82%(24 patients) had intermediate 1 IPSS,14.92% (10 patients) intermediate 2,just five patients had a high risque with range of 7%.Reviesed IPSS(R-IPSS) was also calculated for only 61 patients (78%),9.8% had a very low R-IPSS,44.26% had low risque,29.5 % had intermediate risque,10 patients had high ( 9%) and very high (6,55%) risque. Concerning management, we decided to wait and see for 41% of patients, 34.6% needed best supportive care, Erythropoietin was prescribed for 28% of our patients, 21.7% received Azacithidine, three of our patients had Hydroxyurea,one of them had Thalidomide, and only two of them have been selected to have an allo stem cell l transplantation . Overall Follow up is about 42 months. The overall survival rate was 77, 78% at 2 years, and 44, 44% at 5 years.
Summary
Despite our few resources our results are the same of most publications concerning survivals in MDS.
Keyword(s): MDS, Patient, Treatment
Session topic: Publication Only